Remission · induction of remission in Crohn's disease
It is very uncertain whether probiotics changes induction of remission compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · induction of remission in Crohn's disease
It is very uncertain whether probiotics changes adverse events leading to withdrawal compared with placebo (very low certainty).
1 finding from 1 review
Clinical relapse · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes clinical relapse (12 to 52 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes withdrawal due to adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (52 weeks) · Patients with quiescent ulcerative colitis
1 finding from 1 review
Maintenance of clinical remission · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes maintenance of clinical remission (52 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (48 to 52 weeks) · Patients with quiescent ulcerative colitis
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
1 finding from 1 review
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (12 weeks) · Patients with quiescent ulcerative colitis
1 finding from 1 review
Clinical relapse · Patients with quiescent ulcerative colitis
Probiotics showed no clear difference in clinical relapse (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review
Maintenance of clinical remission · Patients with quiescent ulcerative colitis
Probiotics showed no clear difference in maintenance of clinical remission (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review
Serious adverse events (52 weeks) · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes serious adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Incidence CDAD: complete case · preventing C. difficile associated diarrhea
Probiotics probably leads to lower incidence CDAD: complete case compared with control (moderate certainty).
1 finding from 1 review
Length of hospital stay · preventing C. difficile associated diarrhea
1 finding from 1 review
CDAD (baseline risk 0‐2%) · preventing C. difficile associated diarrhea
Probiotics showed no clear difference in CDAD (baseline risk 0‐2%) compared with control (moderate certainty).
1 finding from 1 review
CDAD (baseline risk 3‐5%) · preventing C. difficile associated diarrhea
Probiotics showed no clear difference in CDAD (baseline risk 3‐5%) compared with control (low certainty).
1 finding from 1 review
CDAD (baseline risk >5%) · preventing C. difficile associated diarrhea
Probiotics probably leads to lower CDAD (baseline risk >5%) compared with control (moderate certainty).
1 finding from 1 review
Incidence of C. difficile infection: complete case · preventing C. difficile associated diarrhea
Probiotics showed no clear difference in incidence of C. difficile infection: complete case compared with control (moderate certainty).
1 finding from 1 review